Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 30 results.
User Information
Export Records
  1. 1.   C-CBL is required for inhibition of angiogenesis through modulating JAK2/STAT3 activity in ROP development
  2. Chen, Shimei; Sun, Qiao; Sun, Dandan; Willette Brown,Jami; Anderson,Matthew; Gu, Qing; Lewandoski,Mark; Hu, Yinling; Zhu,Feng; Wei, Fang; Zhang, Jian
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020, DEC; 132: 110856.
  1. 2.   Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome
  2. Henríquez, Soledad; Kohen, Paulina; Xu,Xia; Villarroel, Claudio; Muñoz, Alex; Godoy, Ana; Strauss, Jerome F; Devoto, Luigi
  3. Human reproduction (Oxford, England). 2020, JUL; 35(7): 1655-1665.
  1. 3.   Vav1 is Essential for HIF-1a Activation via a Lysosomal VEGFR1-Mediated Degradation Mechanism in Endothelial Cells
  2. Hong,Jaewoo; Min,Yongfen; Wuest, Todd; Lin,Charles
  3. Cancers. 2020, JUN; 12(6): E1374.
  1. 4.   Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
  2. Ma, Lichun; Hernandez,Maria; Zhao,Yongmei; Mehta,Monika; Tran,Bao; Kelly,Michael; Rae,Zachary; Hernandez, Jonathan M; Davis, Jeremy L; Martin, Sean P; Kleiner, David E; Hewitt, Stephen M; Ylaya, Kris; Wood, Bradford J; Greten, Tim F; Wang, Xin Wei
  3. Cancer cell. 2019, Oct 14; 36(4): 418-430.
  1. 5.   A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
  2. Zimmer, Alexandra S; Nichols,Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C; Annunziata, Christina M; Lipkowitz, Stanley; Trepel, Jane B; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D; Houston, Nicole D; Lee, Jung-Min
  3. Journal for immunotherapy of cancer. 2019, Jul 25; 7(1): 197.
  1. 6.   Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
  2. El-Behaedi, Salma; Landsman, Rebekah; Rudloff, Michael; Kolyvas, Emily; Albalawy, Rakan; Zhang, Xianyu; Bera, Tapan; Collins, Keith; Kozlov, Serguei; Alewine, Christine
  3. Toxins. 2018, Nov; 10(11): pii: E447.
  1. 7.   Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells
  2. Wu, Hai-Bo; Yang, Shuai; Weng, Hai-Yan; Chen, Qian; Zhao, Xi-Long; Fu, Wen-Juan; Niu, Qin; Ping, Yi-Fang; Wang, Jiming; Zhang, Xia; Yao, Xiao-Hong; Bian, Xiu-Wu
  3. Autophagy. 2017, Sep 2; 13(9): 1528-1542.
  1. 8.   C/EBP-d positively regulates MDSC expansion and endothelial VEGFR2 expression in tumor development
  2. Min, Yongfen; Li, Jingdong; Qu, Peng; Lin, Charles
  3. Oncotarget. 2017, Aug 1; 8(31): 50582-50593.
  1. 9.   TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types
  2. Chaudhary, A.; Hilton, M. B.; Seaman, S.; Haines, D. C.; Stevenson, S.; Lemotte, P. K.; Tschantz, W. R.; Zhang, X. Y. M.; Saha, S.; Fleming, T.; St Croix, B.
  3. Cancer Cell. 2012, Feb; 21(2): 212-226.
  1. 10.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 11.   C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1 alpha
  2. Min, Y.; Ghose, S.; Boelte, K.; Li, J.; Yang, L.; Lin, P. C.
  3. Oncogene. 2011, Dec; 30(49): 4901-4909.
  1. 12.   Supplementation with alpha-Tocopherol or beta-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
  2. Mondu, A. M.; Rager, H. C.; Kopp, W.; Virtamo, J.; Albanes, D.
  3. Journal of Nutrition. 2011, Nov; 141(11): 2030-2034.
  1. 13.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 14.   GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier
  2. Cullen, M.; Elzarrad, M. K.; Seaman, S.; Zudaire, E.; Stevens, J.; Yang, M. Y.; Li, X. J.; Chaudhary, A.; Xu, L. H.; Hilton, M. B.; Logsdon, D.; Hsiao, E.; Stein, E. V.; Cuttitta, F.; Haines, D. C.; Nagashima, K.; Tessarollo, L.; St Croix, B.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Apr; 108(14): 5759-5764.
  1. 15.   Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases
  2. Young, L. R.; VanDyke, R.; Gulleman, P. M.; Inoue, Y.; Brown, K. K.; Schmidt, L. S.; Linehan, W. M.; Hajjar, F.; Kinder, B. W.; Trapnell, B. C.; Bissler, J. J.; Franz, D. N.; McCormack, F. X.
  3. Chest. 2010, Sep; 138(3): 674-681.
  1. 16.   The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
  2. Diaz, R.; Nguewa, P. A.; Diaz-Gonzalez, J. A.; Hamel, E.; Gonzalez-Moreno, O.; Catena, R.; Serrano, D.; Redrado, M.; Sherris, D.; Calvo, A.
  3. British Journal of Cancer. 2009 100(6): 932-940.
  1. 17.   JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells
  2. Yin, Y. M.; Wang, S.; Sun, Y. J.; Matt, Y.; Colburn, N. H.; Shu, Y. Q.; Han, X.
  3. Biomedicine and Pharmacotherapy. 2009 63(6): 429-435.
  1. 18.   Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
  2. Dang, D. T.; Chun, S. Y.; Burkitt, K.; Abe, M.; Chen, S.; Havre, P.; Mabjeesh, N. J.; Heath, E. I.; Vogelzang, N. J.; Cruz-Correa, M.; Blayney, D. W.; Ensminger, W. D.; Croix, B. S.; Dang, N. H.; Dang, L. H.
  3. Cancer Research. 2008 68(6): 1872-1880.
  1. 19.   Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth
  2. Segarra, M.; Williams, C. K.; Sierra, M. D.; Bernardo, M.; McCormick, P. J.; Maric, D.; Regino, C.; Choyke, P.; Tosato, G.
  3. Blood. 2008 112(5): 1904-1911.
  1. 20.   Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR
  2. Yao, X. H.; Ping, Y. F.; Chen, J. H.; Xu, C. P.; Chen, D. L.; Zhang, R.; Wang, J. M.; Bian, X. W.
  3. Journal of Pathology. 2008 215(4): 369-376.
  1. 21.   A novel lipoxygenase inhibitor Nordy attenuates malignant human glioma cell responses to chemotactic and growth stimulating factors
  2. Chen, J. H.; Yao, X. H.; Gong, W.; Hu, J.; Zhou, X. D.; Chen, K.; Liu, H.; Ping, Y. F.; Wang, J. M.; Bian, X. W.
  3. Journal of Neuro-Oncology. 2007, Sep; 84(3): 223-231.
  1. 22.   Targeting hypoxia cell signaling for cancer therapy
  2. Melillo, G.
  3. Cancer and Metastasis Reviews. 2007, Jun; 26(2): 341-352.
  1. 23.   Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors
  2. Yazawa, H.; Murakami, T.; Li, H. M.; Back, T.; Kurosaka, K.; Suzuki, Y.; Shorts, L.; Akiyama, Y.; Maruyama, K.; Parsoneault, E.; Wiltrout, R. H.; Watanabe, M.
  3. Cancer Gene Therapy. 2006, Nov; 13(11): 993-1001.
  1. 24.   Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas
  2. Bian, X. W.; Jiang, X. F.; Chen, J. H.; Bai, J. S.; Dai, C.; Wang, Q. L.; Lu, J. Y.; Zhao, W.; Xin, R.; Liu, M. Y.; Shi, J. Q.; Wang, J. M.
  3. International Immunopharmacology. 2006, Jan; 6(1): 90-99.
  1. 25.   Inhibition of pathologic retinal neovascularization by alpha-defensins
  2. Economopoulou, M.; Bdeir, K.; Cines, D. B.; Fogt, F.; Bdeir, Y.; Lubkowski, J.; Lu, W. Y.; Preissner, K. T.; Hammes, H. P.; Chavakis, T.
  3. Blood. 2005, DEC 1; 106(12): 3831-3838.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel